The effect of telomerase template antagonist GRN163L on Bone-Marrow-Derived rat mMesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6

Stem Cell Reviews and Reports

Volumn 6, Issue 2, 2010, Pages 224-233

  Tokcaer Keskin, Zeynep ^a   Dikmen, Zeliha G ^b   Ayaloglu Butun, Fatma ^a   Gultekin, Sinan ^a   Gryaznov, Sergei M ^c   Akcali, Kamil Can ^a  

^a BILKENT UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c GERON CORPORATION   (United States)

Author keywords

Cdk4; Cdk6; Cyclin D1; GRN163L; Mesenchymal stem cells; Telomerase

Indexed keywords

CDK4 PROTEIN, RAT; CDK6 PROTEIN, MOUSE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; GRN163L PEPTIDE; OLIGONUCLEOTIDE; TELOMERASE;

ANIMAL; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; CELL DIFFERENTIATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; MESENCHYMAL STEM CELL; METABOLISM; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MESENCHYMAL STROMA CELL;

ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL DIFFERENTIATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; MESENCHYMAL STEM CELLS; OLIGONUCLEOTIDES; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; MESENCHYMAL STROMAL CELLS;

RATTUS;

EID: 77953914542     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-010-9124-7     Document Type: Article

References (32)

1. Greider, C. W., & Blackburn, E. H. (1985). Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell, 43, 405-413.
2. Greider, C. W., & Blackburn, E. H. (2004). Tracking telomerase. Cell, 116, 83-86.
3. Shay, J. W., & Wright, W. E. (2006). Telomerase therapeutics for cancer: challenges and new directions. Nature Reviews Drug Discovery, 5, 577-584.
4. Shay, J. W., & Keith, W. N. (2008). Targeting telomerase for cancer therapeutics. British Journal of Cancer, 98, 677-683.
5. Keith, W. N., Thomson, C. M., Howcroft, J., Maitland, N. J., & Shay, J. W. (2007). Seeding drug discovery: Integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells. Drug Discovery Today, 12, 15-16.
6. Gellert, G., Dikmen, Z., Wright, W. E., Gryaznov, S., & Shay, J. W. (2006). Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Research and Treatment, 96, 73-81.
7. Wang, E. S., Wu, K., Chin, A. C., et al. (2004). Telomerase inhibition with an oligonucleotide telomerase template antagonist: In vitro and in vivo studies in multiple myeloma and lymphoma. Blood, 103, 258-266.
8. Dikmen, Z. G., Gellert, G. C., Jackson, S., et al. (2005). In vivo inhibition of lung cancer by GRN163L: A novel human telomerase inhibitor. Cancer Research, 65, 7866-7873.
9. Cong, Y., & Shay, J. W. (2008). Actions of human telomerase beyond telomeres. Cell Research, 18, 725-732.
10. Friedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970). The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell and Tissue Kinetics, 3, 393-403.
11. da Silva, M. L., Caplan, A. I., & Nardi, N. B. (2008). In search of the in vivo identity of mesenchymal stem cells. Stem Cells, 26, 2287-2299.
12. Tokcaer-Keskin, Z., Akar, A. R., Ayaloglu-Butun, F., et al. (2009). Timing of induction of cardiomyocyte differentiation for in vitro cultured mesenchymal stem cells: A perspective for emergencies. Canadian Journal of Physiology and Pharmacology, 87, 143-150.
13. Karp, J. M., & Leng-Teo, G. S. (2009). Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell, 4, 206-216.
14. Zipori, D. (2006). The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle. Cancer and Metastasis Reviews, 25, 459-467.
15. Reiser, J., Zhang, X. Y., Hemenway, C. S., Mondal, D., Pradhan, L., & La Russa, V. F. (2005). Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opinion on Biological Therapy, 5, 1571-1584.
16. Bradford, M. M. (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 74, 248-254.
17. Molckovsky, A., & Siu, L. L. (2008). First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting. Journal of Hematology and Oncology, 1, 20.
18. Serakinci, N., Graakjaer, J., & Kolvraa, S. (2008). Telomere stability and telomerase in mesenchymal stem cells. Biochimie, 90, 33-40.
19. Carpenter, M. K., Rosler, E. S., Fisk, G. J., et al. (2004). Properties of four human embryonic stem cell lines maintained in a feeder-free culture system. Developmental Dynamics, 229, 243-258.
20. Flores, I., Benetti, R., & Blasco, M. A. (2006). Telomerase regulation and stem cell behaviour. Current Opinion in Cell Biology, 18, 254-260.
21. Phinney, D. G., & Prockop, D. J. (2007). Concise review: Mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair-current views. Stem Cells, 25, 2896-2902.
22. Simonsen, J. L., Rosada, C., Serakinci, N., et al. (2002). Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nature Biotechnology, 20, 592-596.
23. Liu, L., DiGirolamo, C. M., Navarro, P. A., Blasco, M. A., & Keefe, D. L. (2004). Telomerase deficiency impairs differentiation of mesenchymal stem cells. Experimental Cell Research, 294, 1-8.
24. Shay, J. W., & Wright, W. E. (2007). Hallmarks of telomeres in ageing research. Journal of Pathology, 211, 114-123.
25. Jackson, S. R., Zhu, C. H., Paulson, V., et al. (2007). Anti-adhesive effects of GRN163L-an oligonucleotide N3′ → P5′ thiophosphoramidate targeting telomerase. Cancer Research, 67, 1121-1129.
26. Goldblatt, E. M., Gentry, E. R., Fox, M. J., Gryaznov, S. M., Shen, C., & Herbert, B. S. (2009). The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Molecular Cancer Therapeutics, 8, 2027-2035.
27. Stenderup, K., Justesen, J., Clausen, C., & Kassem, M. (2003). Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone, 33, 919-926.
28. Kretlow, J. D., Jin, Y. Q., Liu, W., et al. (2008). Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biology, 9, 60-72.
29. Sethe, S., Scutt, A., & Stolzing, A. (2006). Aging of mesenchymal stem cells. Ageing Research Reviews, 5, 91-116.
30. Schieker, M., Pautke, C., Reitz, K., et al. (2004). The use of four-colour immunofluorescence techniques to identify mesenchymal stem cells. Journal of Anatomy, 204, 133-139.
31. Zimmermann, S., Voss, M., Kaiser, S., Kapp, U., Waller, C. F., & Martens, U. M. (2003). Lack of telomerase activity in human mesenchymal stem cells. Leukemia, 17, 1146-1149.
32. Galderisi, U., Helmbold, H., Squillaro, T., et al. (2009). In vitro senescence of rat mesenchymal stem cells is accompanied by downregulation of stemness-related and DNA damage repair genes. Stem Cells and Development, 18, 1-9.